Table 1. Patients’ characteristics.
| FSS |
Radical surgery
|
||||
|---|---|---|---|---|---|
| Total | Group A | Group B | Group C | P-value | |
| Total | 572 | 74 | 52 | 446 | |
| Age | <0.0001 | ||||
| ⩽40 | 126 | 74 | 52 | 0 | |
| >40 | 446 | 0 | 0 | 446 | |
| FIGO stage | 0.0291 | ||||
| IA | 191 | 36 | 18 | 137 | |
| IB | 7 | 1 | 0 | 6 | |
| IC | 374 | 37 | 34 | 303 | |
| IC(r)*1 | 213 | 21 | 21 | 171 | |
| IC(non-r)*2 | 161 | 16 | 13 | 132 | |
| Histological type | 0.0002#1 | ||||
| Serous | 64 | 4 | 4 | 56 | |
| Mucinous | 150 | 43 | 18 | 89 | |
| Clear-cell | 212 | 13 | 17 | 182 | |
| Endometrioid | 128 | 14 | 11 | 103 | |
| Others*3 | 18 | 0 | 2 | 16 | |
| Grade | 0.294#2 | ||||
| G1/G2 | 323 | 57 | 33 | 233 | |
| G3 | 37 | 4 | 2 | 31 | |
| NC*4 | 212 | 13 | 17 | 182 | |
| Comprehensive surgical staging surgery | NA | ||||
| Yes | 321 | NC | 24 | 297 | |
| No | 177 | NC | 28 | 149 | |
| FSS | 74 | 74 | NC | NC | |
| Preoperative CA125 value | 0.0003 | ||||
| ⩽35 IU ml–1 | 204 | 29 | 14 | 161 | |
| >35 IU ml–1 | 332 | 33 | 37 | 262 | |
| Unknown | 36 | 12 | 1 | 23 | |
| Peritoneal cytology | 0.145 | ||||
| Negative | 407 | 58 | 35 | 314 | |
| Positive | 165 | 16 | 17 | 132 | |
| Platinum-based chemotherapy | 0.266#3 | ||||
| Taxane plus platinum | 241 | 22 | 16 | 203 | |
| Conventional platinum-based | 205 | 32 | 30 | 143 | |
| None | 126 | 20 | 6 | 100 | |
Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; FSS=fertility-sparing surgery; NC=not classified; NA=not analysed; *1=intraoperative capsule rupture; *2=washing/ascites positive or preoperative capsule rupture; *3=mixed epithelial tumour and undifferentiated carcinoma; *4=grade of clear-cell pathology was not classified. P-values: comparison of groups A with groups B–C; #1=Clear-cell vs non clear-cell, #2=G1/G2 vs G3; #3=platinum-based chemotherapy, present vs absent.